PEGylation is a well established technique that alters the pharmacokinetic properties of bioactive proteins. PEG has been associated with benefits such as reduced dosing schedules as well as the potential to increase uptake in tumors. Quintessence has evaluated the potential benefits of PEG•EVade RNase conjugates as next generation drugs. Multiple families of conjugates, varying the conjugation chemistries as well as EVadeTM RNases, have been investigated. One of these compounds, QBI-211, has been selected as a lead candidate for pre-clinical studies.
Quintessence Biosciences, Inc.
Quintessence Biosciences, Inc. 